ClinicalTrials.gg
WithdrawnNCT06752876GALLOPUpdated Sep 19, 2025

CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy, in Patients With Refractory Systemic Lupus Erythematosus (GALLOP)

A Phase 1 interventional study of CB-010 in Systemic Lupus Erythematosus, Lupus and Lupus Erythematosus, sponsored by Caribou Biosciences, Inc.. Withdrawn. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-09-19.

Primary conditionLupus NephritisRegistry: Lupus Erythematosus, SystemicReclassifiedWhy we changed it
Registry
Lupus Erythematosus, Systemic — the first condition term the registry derived for this study.
ClinicalTrials.gg
Lupus Nephritis
Why
  1. The study's listed conditions name Lupus Nephritis, a narrower term within Lupus Erythematosus, Systemic.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Caribou Biosciences, Inc. · Phase 1, Interventional, and Treatment

Why this study was withdrawn
Sponsor Strategic Pipeline Prioritization with Focus on CB-010 and CB-011 Oncology Programs

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
0
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

This is a Phase 1 study to evaluate the safety and efficacy of a single infusion of CB-010 in patients with refractory Systemic Lupus Erythematosus (SLE) with cohorts for lupus nephritis (LN) and extrarenal lupus (ERL).

Read the detailed description

Participants enrolled can expect to be on the study for a total duration of approximately 2 years, during which there will be a screening period followed by a single administration of CB-010 and then 24 months of safety follow-up and monitoring.

02

Conditions studied

  • Systemic Lupus Erythematosus
  • Lupus
  • Lupus Erythematosus
  • Lupus Nephritis

Browse trials for

Keywords

  • CB-010
  • Lupus nephritis
  • Lupus
  • Extrarenal lupus
  • Autoimmune disease
  • Anti-CD19 CAR-T therapy
  • Cell therapy
03

In context

Lupus Nephritis Reclassified

343 studies on the registry are indexed under Lupus Nephritis; 137 are open to participants now.

Browse Lupus Nephritis studies →

Lead sponsor

Caribou Biosciences, Inc. is the lead sponsor of 5 studies on the registry; 2 are open to participants now.

Compared within Lupus Nephritis, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Lupus Erythematosus, Systemic. The counts are of registry records indexed under each term, refreshed daily. How we classify →

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Clinical diagnosis of SLE according to 2019 EULAR/ACR classification criteria for at least 6 months
  • Cohort 1 LN:

    1. Class III or IV lupus nephritis
    2. Urine protein-to-creatinine ratio (UPCR) ≥ 0.8 mg/mg
    3. to and at least 2 therapies
  • Cohort 2 ERL (Patients with class I and II LN may be included in the ERL cohort if their SLEDAI-2K is ≥ 8):

    1. SLEDAI-2K ≥ 8
    2. Refractory to glucocorticoids, and at least 2 immunosuppressive therapies
  • Adequate renal, hepatic, pulmonary, and cardiac function, with specific laboratory criteria
  • Females must be either of nonchildbearing potential, defined as or surgically sterile or agree to use a highly effective double barrier method of or vasectomized partner

Exclusion criteria

Exclusion Criteria:

  • Has active severe central nervous system (CNS) lupus in the previous 3 months from planned LD start date
  • Has received any other treatment for any indication within the 4 weeks or 5 half-lives
  • Prior treatment with cellular therapy (genetically modified cells), gene therapy directed at any target, allogenic or stem cell transplant or organ transplant
  • History of infection with or evidence of or C virus infection
  • History of to Cyclophosphamide, Fludarabine, or any of the components of CB-010
  • Received a ≤ 6 weeks prior to start of LD
  • Patients for whom magnetic resonance imaging (MRI) studies are or who cannot tolerate them
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    Cohort 1 Lupus Nephritis (LN)

    Drug: CB-010

  • Experimental
    Cohort 2 Extrarenal Lupus (ERL)

    Drug: CB-010

Interventions

  • DrugCB-010

    CB-010 allogeneic CAR-T cell therapy, Cyclophosphamide and Fludarabine chemotherapy for lymphodepletion

06

What researchers measure

Primary outcomes

  1. Incidence of critical safety events (CSEs) ≤ 28days after CB-010 infusion

    Time frame: Through 28 days

  2. Incidence of treatment emergent adverse events (TEAEs), serious adverse events (SAEs), and adverse events of special interest (AESIs)

    Time frame: Through end of study (approximately 2 years)

Secondary outcomes

  1. To characterize the PK profile of a single infusion of CB-010 (i.e., CB-010 expansion and persistence)

    Concentration of CB-010 in blood samples over time

    Time frame: Through end of study (approximately 2 years)

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Dec 2027; primary completion for Apr 2029, 16 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 18, 2024
First posted
Dec 31, 2024
StartEst.
Dec 2027
Primary completionEst.
Apr 2029
CompletionEst.
Apr 2029
Last update
Sep 19, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 19, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06752876
Lead sponsor
Caribou Biosciences, Inc.
Responsible party
Sponsor
First posted
Dec 31, 2024
Start date
Dec 2027 (estimated)
Primary completion
Apr 2029 (estimated)
Completion
Apr 2029 (estimated)
Last update
Sep 19, 2025

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion